Just out today, Feb 24th: Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

[JLS1]

Can anyone post the entire article? I don't have access. Here's the link:

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

prostatecancernewstoday.com...

[tango65]

Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.

Authors:

Neeraj Agarwal, Yohann Loriot, Bradley Alexander McGregor, Robert Dreicer, Tanya B. Dorff, Benjamin Louis Maughan, William Kevin Kelly, Lance C. Pagliaro, Sandy Srinivas, Christian Michael Squillante et al

Research Funding:

Exelixis, Inc.

Background:

C may enhance response to immune checkpoint inhibitors by promoting an immune-permissive microenvironment. COSMIC-021 (NCT03170960), a multinational phase 1b study, is evaluating the combination of C with A in various solid tumors. We report interim results from Cohort 6 in mCRPC.

Methods:

Eligible pts were required to have radiographic progression in soft tissue after enzalutamide and/or abiraterone, measurable disease, and an ECOG PS of 0 or 1. Prior chemotherapy for mCSPC was permitted. Pts received C 40 mg PO qd and A 1200 mg IV q3w. CT/MRI scans were performed q6w for 52w and q12w thereafter. Bone scans were performed q12w. The primary endpoint is ORR per RECIST 1.1. Other endpoints include safety, ORR per irRECIST, duration of response (DOR), PFS, and OS.

Results:

As of Oct 2019, 44 mCRPC pts were enrolled with a median follow-up of 10.6 mo (range 3.4+, 17.9). Median age was 70 y (range 49, 90), 50% had ECOG PS 1, 34% had visceral metastases, and 61% had extrapelvic lymph node metastases. 27% of pts had prior docetaxel and 52% had ≥2 prior novel hormonal therapies. The most common any grade TEAEs were fatigue (57%), nausea (48%), decreased appetite (45%), diarrhea (39%), PPE (32%), and vomiting (32%). One Grade 5 TRAE of dehydration was reported in a 90 y/o. Median duration of treatment was 5.3 mo. The ORR per RECIST 1.1 among all pts was 32% (2 CRs [4.5%] and 12 PRs [27%]); 21 (48%) pts had SD giving a disease control rate of 80% in all pts. One pt with initial PD per RECIST 1.1 had an irPR per irRECIST. ORR per RECIST 1.1 was 33% in 36 pts with high-risk clinical features (visceral and/or extrapelvic lymph node metastases). Median DOR for all pts with response per RECIST 1.1 was 8.3 mo (range 1.38+, 9.76+). In 12 responders with at least 1 post-baseline PSA evaluation, 8 (67%) had a PSA decline ≥50%.

Conclusions:

The combination of C+A had a tolerable safety profile and demonstrated clinically meaningful activity with durable responses in men with mCRPC. Given the encouraging activity in these pts, especially in those with visceral and/or extra pelvic lymph node metastases, further evaluation of C+A in men with mCRPC is being pursued. Clinical trial information: NCT03170960

---------------------

en.wikipedia.org/wiki/Caboz...

Atezolizumab is a PDL-1 inhibitor,

en.wikipedia.org/wiki/Caboz...

Both drugs could have significant side effects:

rxlist.com/tecentriq-drug.htm

rxlist.com/cabometyx-drug.htm